Klimadynon

Cimicifuga racemosa dry extract, the active ingredient in Klimadynon, is a herbal botanical presented as a dry extract for oral use. It is traditionally employed to support women experiencing menopausal symptoms, particularly vasomotor disturbances such as hot flashes and night sweats. Klimadynon is manufactured in the European Union and complies with applicable quality standards for botanical medicines.

GNH USA supplies Klimadynon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Klimadynon, containing black cohosh dry extract, is used primarily in the management of menopausal symptoms.

- Menopausal hot flashes: reduction in frequency and intensity of episodes. - Night sweats: alleviation of disruptive nocturnal sweating. - Mood swings associated with menopause: support for emotional stability. - Sleep disturbances during menopause: improvement in sleep quality. - Minor vaginal dryness: modest relief of discomfort.

Klimadynon is generally well tolerated, but some users may experience adverse reactions.

Common Side Effects: - Mild gastrointestinal upset, such as nausea or stomach discomfort. - Headache. - Dizziness. - Skin rash or mild itching. - Fatigue. - Mild insomnia.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis). - Significant liver enzyme elevation. - Unexplained bleeding or bruising. - Thromboembolic events. - Severe hypertension. - Acute liver injury.

When considering Klimadynon, certain precautions should be observed.

- Pregnancy: avoid use unless specifically advised by a healthcare professional. - Breastfeeding: exercise caution and consult a physician before use. - Liver disease: monitor liver function during therapy. - Concurrent hormonal therapy: assess potential additive estrogenic effects. - Known allergy to black cohosh: contraindicated. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Klimadynon may interact with other medicines; awareness of these interactions helps ensure safe use.

Major Interactions (Avoid): - Concomitant estrogen‑containing therapies: may increase overall estrogenic activity. - Anticoagulants (e.g., warfarin): potential for enhanced bleeding risk. - Selective serotonin reuptake inhibitors (SSRIs): possible serotonin syndrome.

Moderate Interactions (Monitor Closely): - Hormonal contraceptives: may alter contraceptive effectiveness. - Lithium: potential increase in lithium serum levels. - CYP450 substrate drugs: possible modulation of metabolism leading to altered drug concentrations.